Logo
KENALOG Injection 40mg/1mL IM Injection 1ml x 1 vial (Single)

KENALOG Injection 40mg/1mL IM Injection 1ml x 1 vial (Single)

Kenalog

Prescription corticosteroid injection
  • UK marketing authorisation as a prescription Only medicinal product
  • Manufactured in compliance with Good Manufacturing Practice (GMP) for medicinal products
  • Regulated by the UK Medicines and Healthcare products Regulatory Agency (MHRA)
Triamcinolone acetonide depot corticosteroid (intramuscular)

Description

KENALOG Injection 40mg/1mL is a long-acting corticosteroid preparation containing triamcinolone acetonide 40 mg per 1 mL in a sterile aqueous suspension, formulated for deep intramuscular administration. It provides prolonged anti-inflammatory and immunosuppressive effects and is used to treat a wide range of inflammatory and allergic conditions, including severe allergic reactions, rheumatic and musculoskeletal disorders, dermatological flare-ups and other systemic inflammatory diseases where depot corticosteroid therapy is indicated. This single 1 mL vial presentation is intended for professional use in controlled medical environments.

Bnefits

  • Provides potent and prolonged anti-inflammatory and immunosuppressive effects from a single depot injection
  • Reduces pain, swelling, redness and discomfort associated with acute and chronic inflammatory conditions
  • Useful where long-term corticosteroid action is required but daily oral dosing is not ideal or practical
  • Supports management of severe allergies, dermatologic flare-ups, musculoskeletal inflammation and certain autoimmune-related symptoms
  • Slow-release action delivers sustained therapeutic levels for several weeks, aiding long-term symptom control
  • Single 1 mL vial format offers a precise, ready-to-use dose for clinic and pharmacy use

Indications

  • Systemic treatment via deep intramuscular injection for conditions where corticosteroid therapy is indicated, including:
  • • Severe allergic states (e.g. severe seasonal or perennial allergic rhinitis, severe asthma, drug hypersensitivity reactions) when other treatments are inadequate
  • • Rheumatic and musculoskeletal disorders (e.g. rheumatoid arthritis, osteoarthritis with inflammatory features, bursitis, tendinitis, sciatica) when systemic steroids are required
  • • Dermatological diseases (e.g. severe psoriasis, eczema, dermatitis, pemphigus) requiring systemic corticosteroid therapy
  • • Collagen and autoimmune disorders (e.g. systemic lupus erythematosus, acute rheumatic carditis) as part of a comprehensive treatment plan
  • • Other endocrine, respiratory, gastrointestinal, haematological or neoplastic conditions where systemic corticosteroids are recommended according to specialist guidance
  • Kenalog may also be used in certain clinical settings for severe inflammatory and allergic conditions under specialist supervision, with dosing and duration tailored to the individual patient.

Composition

  • Triamcinolone acetonide 40 mg/mL (active ingredient)
  • Benzyl alcohol 15 mg/mL (preservative)
  • Carboxymethylcellulose sodium (carmellose sodium)
  • Polysorbate 80
  • Sodium chloride
  • Water for injections
  • Sodium hydroxide and/or hydrochloric acid (for pH adjustment)

Formulation

  • Sterile aqueous suspension for injection
  • Concentration: 40 mg/mL triamcinolone acetonide
  • Depot formulation designed for deep intramuscular administration to provide prolonged action
  • Not suitable for intravenous, intrathecal, epidural, intraocular or intradermal injection

Packaging

  • Single 1 mL glass vial containing sterile aqueous suspension (40 mg triamcinolone acetonide per vial)
  • Prescription-only medicine intended for single-use; any unused suspension must be discarded after opening

Usage

  • For deep intramuscular use only; must be administered by a suitably trained healthcare professional using strict aseptic technique.
  • Typical adult systemic dose is around 40 mg (1 mL) as a single deep intramuscular injection into a large muscle (e.g. upper outer quadrant of the gluteal muscle); the exact dose, frequency and duration must be individualised by the prescriber based on the condition and patient factors.
  • Because Kenalog is a depot corticosteroid, repeat injections should not be given routinely; the interval between doses should be guided by clinical response and the risk of systemic side effects.
  • The vial should be shaken gently before use to ensure a uniform suspension and inspected visually for particulate matter or discolouration; do not use if the suspension appears abnormal.
  • Use an appropriate needle length to ensure deep intramuscular delivery and avoid subcutaneous injection, which increases the risk of local tissue atrophy.
  • Do not administer by intravenous, intrathecal, epidural, intraocular or intradermal routes.
  • If patients are receiving repeated or high-dose systemic corticosteroid therapy, treatment should not usually be stopped abruptly; tapering or supplemental dosing during physiological stress may be needed according to clinical judgement and official guidance.
  • Always refer to the full Summary of Product Characteristics and local prescribing guidelines for detailed dosing, precautions and monitoring requirements.

Contraindications

  • Hypersensitivity to triamcinolone acetonide, benzyl alcohol or any excipient in the formulation
  • Systemic fungal infections or uncontrolled systemic infections unless appropriate anti-infective therapy is given
  • Premature babies and neonates due to the benzyl alcohol content
  • Situations where corticosteroid therapy is otherwise contraindicated or requires extreme caution (e.g. untreated peptic ulcer, severe osteoporosis, uncontrolled diabetes or hypertension, Cushing’s syndrome), as per specialist and product guidance
  • Use via intravenous, intrathecal, epidural, intradermal or intraocular routes is contraindicated

Adverse Effects

  • Local: injection-site pain, irritation, bruising, sterile abscess, local tissue or fat atrophy and skin depigmentation if not injected deeply intramuscularly
  • Endocrine/metabolic: adrenal suppression, Cushingoid features (moon face, truncal obesity), weight gain, hyperglycaemia or worsening of diabetes, fluid and sodium retention with oedema, hypokalaemia, menstrual irregularities
  • Musculoskeletal: muscle weakness, myopathy, osteoporosis, osteonecrosis, tendon rupture (especially with local steroid administration), growth suppression in children with prolonged systemic use
  • Immune/infectious: increased susceptibility to infections, masking of infection signs, reactivation of latent infections (e.g. tuberculosis, herpes), impaired wound healing
  • Gastrointestinal: dyspepsia, peptic ulcer, gastrointestinal bleeding or perforation, pancreatitis
  • Neuropsychiatric: mood changes (euphoria, depression, irritability), insomnia, anxiety, psychotic reactions, confusion, seizures (rare)
  • Ophthalmic: cataracts, glaucoma, raised intraocular pressure, central serous chorioretinopathy (with systemic corticosteroids)
  • Cardiovascular and thromboembolic: hypertension, fluid overload, increased risk of thromboembolic events in susceptible patients
  • Dermatologic: skin thinning, striae, acneiform eruptions, bruising, delayed wound healing, urticaria, angioedema, rare anaphylactic or anaphylactoid reactions

Storage Conditions

  • Do not store above 25°C.
  • Do not freeze.
  • Store the vial in the original carton to protect from light.
  • Keep in an upright position where possible.
  • Keep out of the sight and reach of children.
  • Single-use only; discard any unused suspension after first opening.
  • Do not use after the expiry date printed on the packaging.

Duration

Highly individual and indication-dependent; a single intramuscular depot dose may provide clinical benefit for several weeks. Repeat dosing intervals are determined by the prescribing clinician based on symptom control, underlying condition and risk of adverse effects.

Onset

Systemic corticosteroid effects typically develop within 24\u201348 hours after intramuscular injection, with anti-inflammatory benefits often persisting for several weeks due to the slow-release depot formulation.

Browse more Prescription corticosteroid injection

Top Treatments

Top Cities in the UK